Metra Biosystems' Alkphase-B
This article was originally published in The Gray Sheet
Executive SummaryFirm's serum-based lab test for bone formation receives FDA clearance May 27 to monitor patient response to anti-resorptive therapies, such as Merck's Fosamax (alendronate) and estrogen, in the treatment and prevention of osteoporosis. The test also is cleared for use as a predictor of skeletal response to hormone replacement therapy, the firm says. Alkphase-B originally was cleared in August 1995 for aiding in the management of Paget's disease
You may also be interested in...
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.